Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Sundram

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Human Psychopharmacology|October 22, 2025
Scopolamine's Anticholinergic Effects on EEG Spectral, Aperiodic, Complexity, Microstates, and Heart Rate VariabilityJoseph C C Chen, Rachael L Sumner, Eric B Thorstensen, et al.
Journal of Neurodevelopmental Disorders|December 1, 2011
White matter microstructure in 22q11 deletion syndrome: a pilot diffusion tensor imaging and voxel-based morphometry study of children and adolescentsFrederick Sundram, Linda E Campbell, Rayna Azuma, et al.
Journal of Psychopharmacology (Oxford, England)|March 30, 2021
A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant propertiesRachael L Sumner, Emme Chacko, Rebecca McMillan, et al.
Pilot and Feasibility Studies|February 12, 2024
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patientsAlesha Wells, A P Suresh Muthukumaraswamy, Eva Morunga, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Human Psychopharmacology|October 22, 2025
Scopolamine's Anticholinergic Effects on EEG Spectral, Aperiodic, Complexity, Microstates, and Heart Rate VariabilityJoseph C C Chen, Rachael L Sumner, Eric B Thorstensen, et al.
Journal of Neurodevelopmental Disorders|December 1, 2011
White matter microstructure in 22q11 deletion syndrome: a pilot diffusion tensor imaging and voxel-based morphometry study of children and adolescentsFrederick Sundram, Linda E Campbell, Rayna Azuma, et al.
Journal of Psychopharmacology (Oxford, England)|March 30, 2021
A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant propertiesRachael L Sumner, Emme Chacko, Rebecca McMillan, et al.
Pilot and Feasibility Studies|February 12, 2024
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patientsAlesha Wells, A P Suresh Muthukumaraswamy, Eva Morunga, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Pageof 8